Ivicentamab

依维妥单抗

Report date: 2023/09/14 20:02:05

Base Information

Drug NameIvicentamab

Drug Alias NameDuoHexaBody-CD37HexaBody®-CD37GEN-3009

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionLeukocyte antigen CD37 antagonists

TargetsLeukocyte antigen CD37

Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited StatesNetherlands +[5]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGenmab A/S Abbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenmab A/S Abbvie Inc

Active IndicationsN/A

Inactive IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[7]

Other Information

ATC CodeN/A